CSE:AGN - Post Discussion
Post by
bmreed on Apr 05, 2023 12:38pm
News Update: $AGN CEO Chris Moreau - Phase 1 Trial AP-188
News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Phase 1 Trial for AP-188 - Doses 2nd Cohort - https://youtu.be/2XM7SC5iQaI
Algernon Pharmaceuticals Inc.'s subsidiary, Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating-dose phase 1 clinical study of an intravenous formulation of AP-188.
Be the first to comment on this post